Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Top 20 Shareholders, March 2019

PAA Top 20 as at 260319

Categories: News & Announcements 2019, Top 20 ShareholdersBy PharmAust March 27, 2019

Related posts

Top 20 Shareholders
August 1, 2022

July 1, Top 20 Shareholders
July 1, 2022

June 1, Top 20 Shareholders
June 1, 2022

May 1, Top 20 Shareholders
May 1, 2022

April 1, Top 20 Shareholders
April 1, 2022

March 1, Top 20 Shareholders
March 1, 2022

Recent Articles

Top 20 Shareholders
August 1, 2022
PharmAust opens door to billion-dollar markets, following MPL trial successes
August 1, 2022
Broker JP Equity says PharmAust has multiple avenues to $US 1 billion+ success
July 27, 2022
JP Equity Research Report
July 22, 2022

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAust Follow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer, viral and neurological diseases. ASX: $PAA FSE: $ECQ

Retweet on Twitter PharmAust Retweeted

PharmAust @pharmaust ·

25 Jul

PharmAust is pleased to announce that leading Australian broking and corporate advisory firm, @JPEquityPartner, has updated their research coverage on $PAA

A full copy of the research note is available for download here 👉 https://www.pharmaust.com/jp-equity-research-report/

Reply on Twitter 1551424206805405699 Retweet on Twitter 1551424206805405699 3 Like on Twitter 1551424206805405699 13 Twitter 1551424206805405699

Load More

Copyright © 2020 Pharmaust. All rights reserved.

nil

Website Design & Digital Marketing Perth by Total Click Solutions